Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 1 - Studien 1 bis 6 von insgesamt 6
- Rekrutierung läuftAdvancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotypingMolekulare Marker
- Rekrutierung läuftA phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in relapsed lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition
- Rekrutierung läuftFirst Line Ipilimumab+Nivolumab Combined with two cycles of Chemotherapy in NSCLC [FINN]
- Rekrutierung läuftAn open-Label, multi-Center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued Treatment with ceritinibMolekulare Marker
- Rekrutierung läuftEfficacy Comparison of Dostarlimab Plus Chemotherapy vs Pembrolizumab plus Chemotherapy in Participants with metatstatic non-squamous non-small Cell Lung
- Rekrutierung läuft
TUMOR-AGNOSTIC PRECISION IMMUNOONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL